Toloxatona y depresión. / [Toloxatone and depression]
Acta Psiquiatr. Psicol. Am. Lat
; 37(4): 291-8, 1991 Dec.
Article
em Es
| BINACIS
| ID: bin-38143
Biblioteca responsável:
AR81.4
ABSTRACT
One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamiltons Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanovas Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment (a) No subject was taking antidepressives, (b) Patients age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either [quot ]excellent[quot ] or [quot ]good[quot ] outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrists choice for administering Toloxatone.
Buscar no Google
Coleções:
06-national
/
AR
Base de dados:
BINACIS
Tipo de estudo:
Clinical_trials
Idioma:
Es
Revista:
Acta Psiquiatr. Psicol. Am. Lat
Ano de publicação:
1991
Tipo de documento:
Article
País de publicação:
Argentina